AstraZeneca PLC (LON:AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02. AstraZeneca shares last traded at £139.96, with a volume of 40,274,711 shares changing hands.
Trending Headlines about AstraZeneca
Here are the key news stories impacting AstraZeneca this week:
- Positive Sentiment: Q3 earnings beat expectations: AstraZeneca reported third-quarter revenue of approximately $16.21 billion, up 7% year over year, while earnings per share more than doubled Wall Street’s estimate. The company reaffirmed its fiscal 2026 revenue and core EPS outlook at constant exchange rates, reducing concerns about near-term execution. AstraZeneca Q3 2026 Earnings AstraZeneca Q3 Profit and Guidance
- Positive Sentiment: Pipeline potential remains significant: AstraZeneca’s CEO said upcoming drug trial readouts in 2027 could represent more than $20 billion in potential value, supporting the long-term growth narrative and helping justify the stock’s valuation. AstraZeneca 2027 Trial Readouts
- Positive Sentiment: Cost savings will fund innovation: The company launched a $1.5 billion savings program, with the goal of redirecting resources toward its drug-development pipeline. This could improve operating leverage and support future launches. AstraZeneca Savings Drive
- Positive Sentiment: Analyst confidence strengthened: Jefferies reaffirmed its “buy” rating and set a £175 price target, implying further upside based on its assessment of AstraZeneca’s earnings and pipeline prospects.
- Positive Sentiment: Promising lung-cancer data: A Tagrisso combination achieved a significant survival benefit in a lung-cancer trial, reinforcing the commercial prospects of one of AstraZeneca’s key oncology franchises. Tagrisso Lung Cancer Trial
- Negative Sentiment: Generic competition remains a headwind: AstraZeneca indicated that the loss of exclusivity for Farxiga is weighing on results, although stronger oncology sales are currently more than offsetting the impact. AstraZeneca Cancer Drugs and Farxiga
Wall Street Analyst Weigh In
A number of research firms recently commented on AZN. Berenberg Bank reaffirmed a "buy" rating and issued a £175 price target on shares of AstraZeneca in a research note on Wednesday, October 7th. Jefferies Financial Group reiterated a "buy" rating and set a £175 price target on shares of AstraZeneca in a research report on Friday. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a £117 price objective on shares of AstraZeneca in a research note on Tuesday, September 29th. Royal Bank Of Canada began coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They set an "outperform" rating and a £145 price objective for the company. Finally, Citigroup upped their target price on AstraZeneca from £175 to £178 and gave the stock a "buy" rating in a research note on Tuesday, July 28th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of £153.57.
Check Out Our Latest Research Report on AZN
AstraZeneca Stock Performance
The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The company has a market capitalization of £217.06 billion, a price-to-earnings ratio of 20.95, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The stock has a 50 day moving average of £123.07 and a 200 day moving average of £134.30.
Insider Activity
In other news, insider Michel Demare bought 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The stock was bought at an average cost of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is owned by company insiders.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
